Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (2 ops.)
Latest filing published 20 Jun 2024 for Glycomimetics INC, €4,035. Read the official filing
Filing timeline
BuySaleBrian M. Hahn
Insider track record
Disclosed buys
2
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Brian M. Hahn: trading record in brief
This profile gathers the share dealings of Brian M. Hahn in Crescent Biopharma, Inc., where the filings describe the role as finance chief. The record holds 4 filings, for trades running from 9 March 2022 to 18 June 2024.
The open-market side counts 2 purchases for €25k alongside 2 sales for €9,574. The net balance comes to €15k on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2024 alone, the filings show 1 purchase and no sales.
The newest entry dates from 20 June 2024: an open-market purchase of €4,035, in Crescent Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Brian M. Hahn
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
17,500 shares@ US$0.247711.7% of flowCommon StockSEC:0001415889-24-017623:0
Canonical exit: 16 Sept 2024 (T+90)
3,700 shares@ US$1.9519.3% of flowCommon StockSEC:0001209191-23-030636:0
20,000 shares@ US$1.0660.4% of flowCommon StockSEC:0001209191-22-056576:0
Canonical exit: 9 Feb 2023 (T+90)
2,917 shares@ US$1.098.5% of flowCommon StockSEC:0001209191-22-017963:0
4 of 4 declarations
